Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1-an aberrant tyrosine kinase-in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs.
Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma-a case report / A.M. Gruszka, C. Rabascio, L. Cannella, S. Sammassimo, G. Andreola, G. Gregato, M. Faretta, A. Calleri, R. De Molfetta, G. Pruneri, F. Bertolini, M. Alcalay. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 5:(2015 Oct), pp. 14829.1-14829.8. [10.1038/srep14829]
Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma-a case report
G. Gregato;G. Pruneri;M. AlcalayUltimo
2015
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1-an aberrant tyrosine kinase-in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs.File | Dimensione | Formato | |
---|---|---|---|
O58_SciRep_Gruszka_15.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
721.02 kB
Formato
Adobe PDF
|
721.02 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.